Search Results
Your search for all items matches 33486 pages
Showing 101 - 150Survivorship Standards at Commission on Cancer–Accredited Cancer Care Facilities
Only a minority of adult cancer survivors may have access to specialized survivorship services such as those addressing fertility and sexual health issues, and having survivorship standards in place may help cancer centers better provide services that meet the distinct needs of these patients,...
Can Adhering to a Mediterranean Diet Reduce Mortality in Cancer Survivors?
Cancer survivors who adhere to a Mediterranean diet may survive longer and have a reduced risk of cardiovascular-related mortality compared with those who had lower adherence to the diet, according to a recent study published by Bonaccio et al in JACC: CardioOncology. Background The Mediterranean...
Advanced Melanoma: Efficacy of Monoclonal Antibody Doublet
In a phase I trial reported in the Journal of Clinical Oncology, Omid Hamid, MD, and colleagues found that the combination of the human lymphocyte activation gene-3 (LAG-3)-targeting monoclonal antibody fianlimab plus the PD-1–targeting monoclonal antibody cemiplimab-rwlc was active in patients...
Endometrial Thickness in Triage for Endometrial Cancer Among Black Women
In a study reported in JAMA Oncology, Kemi Doll, MD, MSCR, and colleagues found that ultrasonography-measured endometrial thickness was not reliable in triage for diagnosing endometrial cancer among Black women. Study Details The retrospective U.S. multicenter study focused on data from 1,494 women ...
Novel Algorithm May Help to Identify Aggressive Basal Cell Carcinoma
A novel algorithm may help physicians to identify which patients have a highly aggressive subtype of facial basal cell carcinoma, according to a recent study published by Ceder et al in Dermatology Practical & Conceptual. Background Basal cell carcinoma—the most common type of skin...
Exploring Health-Care Provider Attitudes Toward HPV Self-Collection Testing
Investigators found that more than 50% of health-care providers surveyed might offer human papillomavirus (HPV) self-collection testing to their patients if the U.S. Food and Drug Administration (FDA) approved the procedure, according to a recent study published by Fontenot et al in Women’s Health...
American Indian and Alaskan Native Women May Be Less Likely to Undergo Breast Reconstruction
Investigators have identified disparities in the rates of breast reconstruction following mastectomy among American Indian and Alaskan Native women compared with non-Hispanic White women, according to a recent study published by White et al in Plastic and Reconstructive Surgery. Background Breast...
Exercise May Prevent Nerve Damage During Chemotherapy
Physical exercise may help prevent nerve damage in patients receiving chemotherapy, according to a recent study published by Streckmann et al in JAMA Internal Medicine. Background Cancer therapies have improved in recent years. Physicians are no longer concerned just about survival; patients’...
Previously Untreated Intermediate-Risk Rhabdomyosarcoma: Addition of Temsirolimus to Chemotherapy in Young Patients
As reported in The Lancet Oncology by Gupta et al, the phase III Children’s Oncology Group ARST1431 trial showed no event-free survival benefit with the addition of temsirolimus to chemotherapy in previously untreated children, adolescents, or young adults with intermediate-risk rhabdomyosarcoma....
Risk of Adverse Obstetric Outcomes in Adolescent and Young Adult Cancer Survivors
In an English and Welsh study (The Teenage and Young Adult Cancer Survivor Study) reported in The Lancet Oncology, Sunguc et al found that cervical cancer and leukemia survivors have a heightened risk of experiencing several serious obstetric complications. “Therefore, any pregnancy [in these...
MAST Trial: Metformin Does Not Slow Disease Progression of Low-Risk Prostate Cancer
The hypoglycemic agent metformin failed to slow disease progression in men with low-risk localized prostate cancer undergoing active surveillance, according to the results of the randomized, controlled MAST trial reported at the 2024 ASCO Annual Meeting.1 In addition, the use of metformin was...
RELATIVITY-048: Triplet Immunotherapy Shows Activity in Untreated Advanced Melanoma
As a first-line treatment of advanced melanoma, the triplet immunotherapy regimen of nivolumab, relatlimab-rmbw, and ipilimumab produced high response rates and promising progression-free and overall survival in the nonrandomized phase I/II RELATIVITY-048 trial, as reported by Paolo Antonio...
Nonplatinum Chemotherapy Regimen for Advanced Cholangiocarcinoma
Based on the results of the multicenter phase II NIFE-AIO-YMO HEP-0315 trial, which were reported in the Journal of Clinical Oncology by Ettrich et al, first-line palliative treatment with nanoliposomal irinotecan plus fluorouracil and leucovorin appears to be safe and active in patients with...
Previously Untreated EGFR-Mutated Advanced NSCLC: Amivantamab/Lazertinib vs Osimertinib
As reported in The New England Journal of Medicine by Byoung Chul Cho, MD, PhD, and colleagues, the phase III MARIPOSA trial has shown improved progression-free survival with amivantamab-vmjw plus lazertinib vs osimertinib in previously untreated patients with EGFR-mutated advanced non–small cell...
Relapsed or Refractory Multiple Myeloma: Activity of BCMA x CD3 Bispecific Antibody
As reported in the Journal of Clinical Oncology by Bumma et al, the phase II portion of a first-in-human phase I/II trial (LINKER-MM1) showed strong activity with the B-cell maturation antigen (BCMA) x CD3 bispecific antibody linvoseltamab in patients with relapsed or refractory multiple myeloma....
PSA May Be Insufficient to Detect Early Prostate Cancer in Transgender Women
Transgender women receiving hormone therapy may skew artificially low on prostate cancer screening tests, thereby providing false reassurance and potentially delaying diagnosis and treatment, according to a recent study published by Nik-Ahd et al in JAMA. The findings indicated that transgender...
Impact of Cisplatin-Based Chemotherapy on Hearing in Cancer Survivors
Researchers have uncovered the long-term effects of cisplatin-based chemotherapy on the hearing of cancer survivors, according to a recent study published by Sanchez et al in JAMA Oncology. Background Cisplatin is commonly used in chemotherapy to treat a variety of cancer types, including...
Perioperative Nivolumab in Renal Cell Carcinoma
As reported in The Lancet Oncology by Allaf et al, a planned interim analysis of the phase III PROSPER ECOG-ACRIN EA8143 trial showed no recurrence-free survival benefit with perioperative nivolumab vs observation in patients undergoing nephrectomy for high-risk renal cell carcinoma. Study ...
Tai Chi vs Cognitive Behavioral Therapy: Measuring Inflammatory Biomarkers in Breast Cancer Survivors With Insomnia
Both tai chi and cognitive behavioral therapy may reduce insomnia and inflammation and bolster antiviral defenses in breast cancer survivors, according to a recent study published by Irwin et al in Brain, Behavior, and Immunity. Background Chronic insomnia—one of the most prominent symptoms...
New Study Demonstrates Similar Outcomes Between Patients With Protocol Exceptions to Participate in Targeted Therapy Trial and Eligible Participants
Patients with treatment-refractory tumors who received eligibility and testing waivers to participate in a large basket/umbrella oncology trial demonstrated similar rates of clinical benefit and adverse events compared with patients who participated in the trial without waivers, according to recent ...
In Gastroesophageal Cancer, ‘Switch’ Maintenance Improves Outcomes Over Chemotherapy Continuation
In patients with advanced HER2-negative gastric or gastroesophageal junction cancer and disease control after oxaliplatin-based chemotherapy, “switch” maintenance with paclitaxel plus ramucirumab in the phase III ARMANI trial significantly improved both progression-free and overall survival,...
ASCO: SCOTUS Ruling Upends Country’s Regulatory Framework, Threatens to Complicate and Delay Health-Care Delivery
The Association for Clinical Oncology (ASCO) has serious concerns about the impact of the Supreme Court’s rulings in Loper Bright Enterprises v Raimondo and Relentless, Inc. v Department of Commerce on cancer care. These decisions overturned the “Chevron deference” or “Chevron doctrine,” a legal...
ASCO, Friends of Cancer Research Applaud FDA Draft Guidance
The Association for Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) are applauding efforts by the U.S. Food and Drug Administration (FDA) to broaden eligibility criteria for cancer clinical trials in order to include more diverse patient populations. In joint comments submitted on ...
ASCO to Present Ethan Basch, MD, MSc, FASCO, With the Joseph Simone Quality Care Award
ASCO will recognize Ethan Basch, MD, MSc, FASCO, a medical oncologist and Distinguished Professor at the University of North Carolina, with the Joseph Simone Quality Care Award and Lecture at the 2024 ASCO Quality Care Symposium. This year’s meeting will be held in San Francisco and online on...
Primary Breast Cancer: Pretreatment Exercise Level and Distant Recurrence–Free Interval
In a French study (CANTO) reported in the Journal of Clinical Oncology, Soldato et al found that increasing pretreatment exercise levels was associated with a longer distant recurrence–free interval up to a threshold exercise level in patients with primary breast cancer. The benefit of exercise...
Transplant-Eligible Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the CASSIOPEIA Trial
As reported in The Lancet Oncology by Philippe Moreau, MD, and colleagues, long-term follow-up of the phase III CASSIOPEIA trial has shown improved progression-free survival with daratumumab maintenance vs observation both among newly diagnosed patients with transplant-eligible multiple myeloma who ...
Second-Line Therapy With Adagrasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer
Second-line therapy with the KRAS inhibitor adagrasib modestly improved progression-free survival and objective response rate over docetaxel in previously treated patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to the primary analysis of the phase III...
Strategies for Reducing the Risk of Cancers in Patients With Alcohol Dependence
Investigators have uncovered the potential benefit of undergoing alcohol rehabilitation and maintaining abstinence in patients with alcohol dependence at risk of developing alcohol-associated cancers, according to a recent study published by Schwarzinger et al in The Lancet Public Health. The...
Novel Spatial Gene-Signature Approach May Help to Predict Immunotherapy Outcomes in Patients With Melanoma
Researchers have demonstrated that spatial gene signatures may enhance the prediction of immunotherapy outcomes in patients with melanoma, according to a recent study published by Aung et al in Clinical Cancer Research. The current gene signatures used to predict immunotherapy outcomes may lack...
Milana Bergamino Sirvén, MD, PhD, on HER2-Positive Early-Stage Breast Cancer: Molecular Profiling, Prognosis, and Treatment Options
Milana Bergamino Sirvén, MD, PhD, of Spain’s Institute of Cancer Research, discusses her findings on molecular profiling of patients with estrogen receptor–positive, HER2-positive early-stage breast tumors after short-term preoperative endocrine therapy. This study suggests that such profiling may...
Ciara C. O’Sullivan, MD, MBBCh, on HER2-Positive Breast Cancer: Expert Commentary on Treatments Under Study
Ciara C. O’Sullivan, MD, MBBCh, of Mayo Clinic, discusses three studies of treatment for patients with HER2-positive metastatic breast cancer and their clinical implications: the EMERALD trial of eribulin and taxane; the Patricia Cohort C trial of palbociclib plus trastuzumab and endocrine therapy; ...
Neoadjuvant Combination of PD-1 and Angiogenesis Inhibitors in Genomically Unstable Colorectal Cancer: NEOCAP
As reported in The Lancet Oncology by Yu et al, based on results from the ongoing phase II NEOCAP trial, neoadjuvant therapy with the PD-1 inhibitor camrelizumab plus the angiogenesis inhibitor apatinib appears to demonstrate “promising” antitumor activity and a manageable toxicity profile in...
Adding COX-2 Inhibition to Chemotherapy in PIK3CA-Activated Stage III Colon Cancer
In an analysis from the CALGB/SWOG 80702 (Alliance) trial published by Nowak et al in the Journal of Clinical Oncology, researchers found that the addition of the cyclooxygenase 2 (COX-2) inhibitor celecoxib to standard adjuvant chemotherapy was associated with improved disease-free survival and...
FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma
On June 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp (Epkinly), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of systemic therapy. EPCORE ...
Can Chemotherapy Impact the Gut Microbiome in Patients With Breast Cancer?
Researchers have uncovered the impact of chemotherapy on the gut microbiome in patients with breast cancer, according to a recent study published by Otto-Dobos et al in Brain, Behavior, and Immunity. Background Chemotherapy is known to cause behavioral side effects, including cognitive decline....
Novel Biomarker May Be Predictive of Clear Cell Renal Cell Carcinoma Recurrence
Researchers have discovered a biomarker that could help identify which patients with clear cell renal cell carcinoma may be at greater risk of cancer recurrence, according to a recent study published by Mehra et al in JCO Precision Oncology. Background Approximately 3% to 5% of all cancer diagnoses ...
Phase III postMONARCH Trial: Switching to Abemaciclib May Improve Outcomes After Disease Progression
For hormone receptor–positive, HER2-negative advanced breast cancer that has progressed on CDK4/6 inhibition plus endocrine therapy, the CDK4/6 inhibitor abemaciclib plus fulvestrant significantly reduced the risk of further disease progression in the phase III postMONARCH study.1 “The postMONARCH ...
Recurrent or Metastatic HNSCC: First-Line VEGFR2 Plus PD-1 Inhibition
In a single-center phase I/II trial reported in The Lancet Oncology, Douglas Adkins, MD, and colleagues found that the recommended phase II dose of ramucirumab combined with pembrolizumab was active in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell...
ER-Positive Advanced Breast Cancer: Oral SERD Plus Palbociclib in First-Line Setting
As reported in the Journal of Clinical Oncology by Javier Cortés, MD, PhD, and colleagues, the phase III AMEERA-5 trial of first-line treatment with the selective estrogen receptor degrader (SERD) amcenestrant plus palbociclib vs letrozole plus palbociclib in estrogen receptor (ER)-positive,...
New Survey Finds Cancer Drug Shortage Management Remains a Moving Target
The National Comprehensive Cancer Network® (NCCN®) published new results from its latest survey on cancer drug shortages in the United States. This follows data published 1 year ago and 6 months ago illustrating how up to 93% of centers surveyed were experiencing shortages of the crucial...
Can Acupuncture Improve Hormonal Side Effects in Women Undergoing Breast Cancer Therapy?
Acupuncture may be effective at reducing the hormonal side effects of endocrine therapy in women with breast cancer, according to a recent study published by Lu et al in Cancer. Background Although endocrine therapy—which is capable of blocking the hormone signaling that drive some types of...
Early Surveillance in Pediatric Patients Genetically Predisposed to Cancer
Initiating surveillance soon after recognizing a pediatric patient has a genetic predisposition for cancer may improve the identification of early-stage asymptomatic tumors, according to a recent study published by Blake et al in JAMA Oncology. The findings may inform clinical practice following...
Estrogen Alone Increased Ovarian Cancer Incidence and Mortality, Combination Hormone Therapy Did Not
In 2002, the federally funded Women’s Health Initiative (WHI),1 a randomized, placebo-controlled clinical trial investigating menopausal hormone therapy for healthy menopausal women, was abruptly halted when it was determined that taking estrogen and progestin hormones after menopause increased the ...
ASCO Sets Six Guiding Principles for AI in Oncology
ASCO has released “Principles for the Responsible Use of Artificial Intelligence in Oncology,” to guide the Society’s consideration of all aspects of artificial intelligence (AI). With this manuscript, ASCO joins colleagues across medicine in offering principles that should be applied in...
ASCO Issues New Guidance on Cannabis and Cannabinoid Use in Adults With Cancer
Many Americans, including patients with cancer, use cannabis and cannabinoids. In response to this reality, ASCO has issued a guideline for clinicians, adults with cancer, caregivers, and researchers on their medical use.1 The recommendations cover all cancer types and address products ranging from ...
Long-Term Study Finds Most Breast Cancer Survivors Were Able to Preserve Fertility and Achieve Pregnancy After Diagnosis
Research examining fertility and attempts at pregnancy among young women after a breast cancer diagnosis has been hampered by short-term follow-up and a lack of prospective assessment of pregnancy attempts. However, a long-term study investigating fertility outcomes among young women who reported...
Retroperitoneal Lymphadenectomy: Can It Be Safely Omitted for Some Patients With Advanced Ovarian Cancer?
Adding retroperitoneal lymphadenectomy to cytoreductive surgery during primary debulking surgery or interval cytoreductive surgery after neoadjuvant chemotherapy failed to improve progression-free or overall survival in patients with advanced ovarian cancer who have no suspicious nodes, according...
Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
On March 22, 2024, mirvetuximab soravtansine-gynx (Elahere) was granted regular approval for adult patients with folate receptor–alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment...
Tovorafenib in Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
On April 23, 2024, tovorafenib (Ojemda) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for patients aged 6 months and older who have relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation.1 Tovorafenib is a...
DREAMM-8: Belantamab Mafodotin-blmf Shows ‘Robust’ Benefit in Early Relapse of Myeloma
Recent phase III findings support the antibody-drug conjugate belantamab mafodotin-blmf as a treatment option for patients with multiple myeloma in early relapse. Belantamab mafodotin is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA) expressed on multiple myeloma cells,...
